EA200501332A1 - Производные пиримидин-4-она и их применение в качестве модуляторов киназы p38 - Google Patents
Производные пиримидин-4-она и их применение в качестве модуляторов киназы p38Info
- Publication number
- EA200501332A1 EA200501332A1 EA200501332A EA200501332A EA200501332A1 EA 200501332 A1 EA200501332 A1 EA 200501332A1 EA 200501332 A EA200501332 A EA 200501332A EA 200501332 A EA200501332 A EA 200501332A EA 200501332 A1 EA200501332 A1 EA 200501332A1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- compounds
- kinaza
- pyrimidin
- modulators
- derivatives
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 abstract 5
- 238000000034 method Methods 0.000 abstract 2
- 102000043136 MAP kinase family Human genes 0.000 abstract 1
- 108091054455 MAP kinase family Proteins 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 102000002574 p38 Mitogen-Activated Protein Kinases Human genes 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/47—One nitrogen atom and one oxygen or sulfur atom, e.g. cytosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
- A61P33/06—Antimalarials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/02—Antidotes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/32—One oxygen, sulfur or nitrogen atom
- C07D239/34—One oxygen atom
- C07D239/36—One oxygen atom as doubly bound oxygen atom or as unsubstituted hydroxy radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/52—Two oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
Abstract
Описаны соединения формулы I и их фармацевтически приемлемые соли, где R, R, Rи Rтакие, как они определены в данном описании. Данные соединения полезны для лечения заболеваний и состояний, вызванных или осложненных нерегулируемой активностью МАР-киназы р38 и/или TNF. Также описаны фармацевтические композиции, содержащие данные соединения, способы получения данных соединений и способы лечения с использованием данных соединений.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US46012403P | 2003-04-03 | 2003-04-03 | |
PCT/IB2004/001121 WO2004087677A2 (en) | 2003-04-03 | 2004-03-29 | Pyrimidin-4-one derivatives and their use as p38 kinase modulators |
Publications (2)
Publication Number | Publication Date |
---|---|
EA200501332A1 true EA200501332A1 (ru) | 2006-06-30 |
EA009743B1 EA009743B1 (ru) | 2008-04-28 |
Family
ID=33131912
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EA200501332A EA009743B1 (ru) | 2003-04-03 | 2004-03-29 | Производные пиримидин-4-она и их применение в качестве модуляторов киназы p38 |
Country Status (24)
Country | Link |
---|---|
US (1) | US7183287B2 (ru) |
EP (1) | EP1753731A2 (ru) |
JP (1) | JP3981398B1 (ru) |
KR (1) | KR100776120B1 (ru) |
CN (1) | CN1968937A (ru) |
AP (1) | AP2005003403A0 (ru) |
AU (1) | AU2004226165C1 (ru) |
BR (1) | BRPI0408990A (ru) |
CA (1) | CA2521081C (ru) |
CR (1) | CR8007A (ru) |
EA (1) | EA009743B1 (ru) |
EC (1) | ECSP056072A (ru) |
GE (1) | GEP20074255B (ru) |
IS (1) | IS8006A (ru) |
MA (1) | MA27754A1 (ru) |
MX (1) | MXPA05010621A (ru) |
NO (1) | NO20055092L (ru) |
NZ (1) | NZ542139A (ru) |
OA (1) | OA13113A (ru) |
RS (1) | RS20050732A (ru) |
TN (1) | TNSN05250A1 (ru) |
UA (1) | UA81658C2 (ru) |
WO (1) | WO2004087677A2 (ru) |
ZA (1) | ZA200506976B (ru) |
Families Citing this family (38)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20070167621A1 (en) * | 2003-04-03 | 2007-07-19 | Pharmacia Corporation | Substituted pyrimidinones |
PL1778686T3 (pl) | 2004-08-12 | 2009-04-30 | Pfizer | Pochodne triazolopirydynylosulfanylowe jako inhibitory kinazy MAP P38 |
CN101039921A (zh) | 2004-10-13 | 2007-09-19 | 法玛西雅厄普约翰有限责任公司 | 3-[5-氯-4-[(2,4-二氟苄基)氧基]-6-氧代嘧啶-1(6h)-基]-n-(2-羟乙基)-4-甲基苯甲酰胺的晶形 |
CA2580497A1 (en) * | 2004-10-13 | 2006-04-20 | Pharmacia & Upjohn Company Llc | Substituted n-alkylpyrimidinones |
WO2007081901A2 (en) * | 2006-01-05 | 2007-07-19 | The Scripps Research Institute | Pyrimidinone derivatives as protein kinase inhibitors |
CA2640665A1 (en) * | 2006-02-10 | 2007-08-16 | Pfizer Products Inc. | Pyridinone pyrazole urea and pyrimidinone pyrazole urea derivatives |
US7588924B2 (en) | 2006-03-07 | 2009-09-15 | Procter & Gamble Company | Crystal of hypoxia inducible factor 1 alpha prolyl hydroxylase |
EP4095127A1 (en) | 2006-06-26 | 2022-11-30 | Akebia Therapeutics Inc. | Prolyl hydroxylase inhibitors and methods of use |
AU2007287601B2 (en) | 2006-08-25 | 2012-12-20 | Boehringer Ingelheim International Gmbh | New pyridone derivatives with MCH antagonistic activity and medicaments comprising these compounds |
TW200831485A (en) | 2006-12-11 | 2008-08-01 | Boehringer Ingelheim Int | New pyridazine derivatives with MCH antagonistic activity and medicaments comprising these compounds |
CL2008000065A1 (es) * | 2007-01-12 | 2008-09-22 | Smithkline Beecham Corp | Compuestos derivados de glicina n-sustituida, inhibidores de hif prolil hidroxilasas; su proceso de preparacion; composicion farmaceutica que comprende a dichos compuestos; y su uso en el tratamiento de la anemia. |
US8198276B2 (en) * | 2007-06-06 | 2012-06-12 | Xcovery Holding Company Llc | Kinase inhibitor compounds |
WO2010138585A1 (en) * | 2009-05-29 | 2010-12-02 | Merck Sharp & Dohme Corp. | Pyrimidinones as pde10 inhibitors |
MX2012005275A (es) | 2009-11-06 | 2012-06-19 | Aerpio Therapeutics Inc | Composiciones y metodos para tratar colitis. |
US9359300B2 (en) | 2010-12-06 | 2016-06-07 | Confluence Life Sciences, Inc. | Methyl/difluorophenyl-methoxy substituted pyridinone-pyridinyl compounds, methyl-pyridinyl-methoxy substituted pyridinone-pyridinyl compounds, and methyl-pyrimidinyl-methoxy substituted pyridinone-pyridinyl compounds |
WO2012078674A1 (en) | 2010-12-06 | 2012-06-14 | Confluence Life Sciences, Inc. | Substituted indole/indazole-pyrimidinyl compounds |
EP3469907B1 (en) | 2010-12-06 | 2021-03-03 | Aclaris Therapeutics, Inc. | Substituted pyridinone-pyridinyl compounds |
US8563558B2 (en) | 2010-12-06 | 2013-10-22 | Confluence Life Sciences, Inc. | Substituted pyridine urea compounds |
NO2686520T3 (ru) | 2011-06-06 | 2018-03-17 | ||
EP2731942B1 (en) | 2011-07-13 | 2015-09-23 | Novartis AG | Novel 2-piperidin-1-yl-acetamide compounds for use as tankyrase inhibitors |
AP2014007400A0 (en) | 2011-07-13 | 2014-01-31 | Novartis Ag | 4-Piperidinyl compounds for use as tankyrase inhibitors |
US9227982B2 (en) | 2011-07-13 | 2016-01-05 | Novartis Ag | 4-oxo-3,5,7,8-tetrahydro-4H-pyrano[4,3-d]pyrminidinyl compounds for use as tankyrase inhibitors |
US9056110B2 (en) | 2011-12-06 | 2015-06-16 | Confluence Life Sciences, Inc. | Substituted pyrimidinone-phenyl-pyrimidinyl compounds |
JP6129850B2 (ja) * | 2012-01-12 | 2017-05-17 | 武田薬品工業株式会社 | Mch受容体拮抗剤としてのベンゾイミダゾール誘導体 |
JP6186434B2 (ja) | 2012-07-18 | 2017-08-23 | サンシャイン・レイク・ファーマ・カンパニー・リミテッドSunshine Lake Pharma Co.,Ltd. | 窒素複素環誘導体及びその医薬品への応用 |
ES2869048T3 (es) | 2013-06-07 | 2021-10-22 | Aclaris Therapeutics Inc | Compuestos de piridinona-piridinilo sustituidos con metil/fluoro-piridinil-metoxi y compuestos de piridinona-piridinilo sustituidos con fluoro-pirimidinil-metoxi |
LT3007695T (lt) | 2013-06-13 | 2024-03-25 | Akebia Therapeutics, Inc. | Kompozicijos ir būdai, skirti anemijos gydymui |
EP3137169B1 (en) | 2014-05-01 | 2021-11-10 | Celgene Quanticel Research, Inc. | Inhibitors of lysine specific demethylase-1 |
WO2015200619A1 (en) * | 2014-06-26 | 2015-12-30 | Rodin Therapeutics, Inc. | Inhibitors of histone deacetylase |
KR102431436B1 (ko) | 2014-08-29 | 2022-08-10 | 테스 파마 에스.알.엘. | α-아미노-β-카복시뮤콘산 세미알데히드 데카복실라제의 억제제 |
EP3247355A4 (en) | 2015-01-23 | 2018-06-13 | Akebia Therapeutics, Inc. | Solid forms of 2-(5-(3-fluorophenyl)-3-hydroxypicolinamido)acetic acid, compositions, and uses thereof |
PE20180189A1 (es) | 2015-04-01 | 2018-01-23 | Akebia Therapeutics Inc | Composiciones y metodos para el tratamiento de la anemia |
TW202406895A (zh) | 2018-05-09 | 2024-02-16 | 美商阿克比治療有限公司 | 用於製備2-[[5-(3-氯苯基)-3-羥基吡啶-2-羰基]胺基]乙酸之方法 |
EP4125891A1 (en) | 2020-03-27 | 2023-02-08 | Aclaris Therapeutics, Inc. | Process, compositions, and crystalline forms of substituted pyridinone-pyridinyl compounds |
CN112209886A (zh) * | 2020-11-09 | 2021-01-12 | 沈阳药科大学 | 2-(3-氰基-4-烷氧基)苯基嘧啶衍生物及其制备方法和用途 |
EP4313970A1 (en) | 2021-03-31 | 2024-02-07 | Xinthera, Inc. | Mk2 inhibitors and uses thereof |
AU2022307534A1 (en) | 2021-07-09 | 2024-02-22 | Xinthera, Inc. | Pyridinone mk2 inhibitors and uses thereof |
TW202400018A (zh) * | 2022-06-21 | 2024-01-01 | 日商組合化學工業股份有限公司 | 使用鹵乙酸之碸衍生物的製造方法 |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS61205261A (ja) * | 1985-03-08 | 1986-09-11 | Sagami Chem Res Center | 6―置換―5―フルオロウラシル誘導体 |
WO1995011235A1 (en) * | 1993-10-20 | 1995-04-27 | The Upjohn Company | Pyrimidinones as antiarthritic and anti-inflammatories |
HUP0001140A3 (en) * | 1996-12-05 | 2002-05-28 | Amgen Inc Thousand Oaks | Substituted pyrimidinone and pyridone compounds and methods of use |
EP1086085A1 (en) * | 1998-06-12 | 2001-03-28 | Vertex Pharmaceuticals Incorporated | INHIBITORS OF p38 |
AU2247701A (en) * | 1999-10-21 | 2001-04-30 | Merck & Co., Inc. | Gram-positive selective antibacterial compounds, compositions containing such compounds and methods of treatment |
CA2497656A1 (en) * | 2002-08-13 | 2004-02-19 | Warner-Lambert Company Llc | Pyrimidine-2,4-dione derivatives as matrix metalloproteinase inhibitors |
-
2004
- 2004-03-24 US US10/808,146 patent/US7183287B2/en not_active Expired - Fee Related
- 2004-03-29 BR BRPI0408990-1A patent/BRPI0408990A/pt not_active IP Right Cessation
- 2004-03-29 GE GEAP20049005A patent/GEP20074255B/en unknown
- 2004-03-29 WO PCT/IB2004/001121 patent/WO2004087677A2/en active Application Filing
- 2004-03-29 JP JP2006506466A patent/JP3981398B1/ja not_active Expired - Fee Related
- 2004-03-29 MX MXPA05010621A patent/MXPA05010621A/es active IP Right Grant
- 2004-03-29 EA EA200501332A patent/EA009743B1/ru unknown
- 2004-03-29 KR KR1020057018627A patent/KR100776120B1/ko not_active IP Right Cessation
- 2004-03-29 AU AU2004226165A patent/AU2004226165C1/en not_active Ceased
- 2004-03-29 UA UAA200508500A patent/UA81658C2/ru unknown
- 2004-03-29 CA CA2521081A patent/CA2521081C/en not_active Expired - Fee Related
- 2004-03-29 RS YUP-2005/0732A patent/RS20050732A/sr unknown
- 2004-03-29 NZ NZ542139A patent/NZ542139A/en unknown
- 2004-03-29 OA OA1200500271A patent/OA13113A/en unknown
- 2004-03-29 AP AP2005003403A patent/AP2005003403A0/xx unknown
- 2004-03-29 CN CNA2004800156300A patent/CN1968937A/zh active Pending
- 2004-03-29 EP EP04724083A patent/EP1753731A2/en not_active Withdrawn
-
2005
- 2005-08-29 IS IS8006A patent/IS8006A/is unknown
- 2005-08-31 ZA ZA200506976A patent/ZA200506976B/en unknown
- 2005-09-27 CR CR8007A patent/CR8007A/es not_active Application Discontinuation
- 2005-10-03 MA MA28531A patent/MA27754A1/fr unknown
- 2005-10-03 TN TNP2005000250A patent/TNSN05250A1/fr unknown
- 2005-10-03 EC EC2005006072A patent/ECSP056072A/es unknown
- 2005-11-01 NO NO20055092A patent/NO20055092L/no not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
MXPA05010621A (es) | 2005-11-23 |
KR20060006906A (ko) | 2006-01-20 |
BRPI0408990A (pt) | 2006-04-04 |
CN1968937A (zh) | 2007-05-23 |
KR100776120B1 (ko) | 2007-11-16 |
CR8007A (es) | 2006-02-13 |
JP3981398B1 (ja) | 2007-09-26 |
US7183287B2 (en) | 2007-02-27 |
TNSN05250A1 (fr) | 2007-07-10 |
GEP20074255B (en) | 2007-12-10 |
RS20050732A (en) | 2007-08-03 |
NZ542139A (en) | 2008-11-28 |
AU2004226165A2 (en) | 2004-10-14 |
WO2004087677A3 (en) | 2004-12-16 |
US20040242608A1 (en) | 2004-12-02 |
NO20055092L (no) | 2005-11-01 |
AP2005003403A0 (en) | 2005-12-31 |
JP2007528353A (ja) | 2007-10-11 |
OA13113A (en) | 2006-11-10 |
AU2004226165C1 (en) | 2008-07-03 |
ECSP056072A (es) | 2006-03-01 |
UA81658C2 (en) | 2008-01-25 |
MA27754A1 (fr) | 2006-02-01 |
WO2004087677A2 (en) | 2004-10-14 |
ZA200506976B (en) | 2006-10-25 |
IS8006A (is) | 2005-08-29 |
EA009743B1 (ru) | 2008-04-28 |
AU2004226165B2 (en) | 2007-11-08 |
CA2521081C (en) | 2010-09-07 |
CA2521081A1 (en) | 2004-10-14 |
AU2004226165A1 (en) | 2004-10-14 |
EP1753731A2 (en) | 2007-02-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EA200501332A1 (ru) | Производные пиримидин-4-она и их применение в качестве модуляторов киназы p38 | |
AP1822A (en) | Substituted pyridinones as modulators of P38 MAP kinase. | |
TW200517109A (en) | Substituted pyridinones | |
EA200501849A1 (ru) | Производные пиразолохиназолина: способ получения и применение в качестве ингибиторов киназ | |
SE0401971D0 (sv) | Piperidne derivatives | |
CY1109962T1 (el) | Υποκατεστημενες ενωσεις 1,4,8-τριαζασπειρο[4,5]δεκαν-2-ονης για τη θεραπεια παχυσαρκιας | |
EA200600811A1 (ru) | НОВЫЕ ПРОИЗВОДНЫЕ ТЕТРАГИДРОСПИРО {ПИПЕРИДИН-2,7'-ПИРРОЛО [3,2-b]ПИРИДИНА} И НОВЫЕ ПРОИЗВОДНЫЕ ИНДОЛА, ПРИМЕНЕНИЕ ДЛЯ ЛЕЧЕНИЯ РАССТРОЙСТВ, СВЯЗАННЫХ С 5-HT-РЕЦЕПТОРОМ | |
DE60206911D1 (de) | Imidazol-2-carbonsäureamid derivate als raf-kinase-inhibitoren | |
CY1109366T1 (el) | Υποκατεστημενες ενωσεις 1,4,8-τριαζασπειρο[4.5]δεκαν-2-ονης | |
SE0401342D0 (sv) | Therapeutic compounds | |
SE0402762D0 (sv) | Indazole sulphonamide derivatives | |
BR0313385A (pt) | Derivados de pirimidina-2,4-diona como inibidores de metaloproteinase da matriz | |
SE0302573D0 (sv) | Benzimidazole derivatives, compositions containing them, preparation thereof and uses thereof | |
SE0301701D0 (sv) | Benzimidazole derivatives, compositions containing them, preparation thereof and uses thereof | |
TW200626581A (en) | Compounds, compositions containing them, preparation thereof and uses thereof | |
SE0301699D0 (sv) | Benzimidazole derivatives, compositions containing them, preparation thereof and uses thereof | |
SE0300105D0 (sv) | Diarylmethylidene piperdine derivatives, preparations thereof and uses thereof | |
SE0302572D0 (sv) | Benzimidazole derivatives, compositions containing them, preparation thereof and uses thereof | |
NO20053805L (no) | Diarylmetylindenpiperidinderivater, framgangsmate for fremstilling derav, og anvendelse derav | |
SE0403118D0 (sv) | New compounds 2 | |
SE0400285D0 (sv) | Pyrroloquinoline and piperidoquinoline derivatives, preparation thereof, compositions containing them and uses thereof | |
SE0300104D0 (sv) | Diarylmethylidene piperidine derivatives, preparations thereof and uses thereof | |
UA81405C2 (ru) | Замещенные пиридиноны как модуляторы р38 мар киназы | |
SE0400025D0 (sv) | Diarylmethylidene piperidine derivatives, preparations thereof and uses thereof | |
SE0400026D0 (sv) | Diarylmethylidene piperidine derivatives, preparations thereof and uses thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
TK4A | Corrections in published eurasian patents |